Royalty Report: Drugs, Cancer, DNA – Collection: 372419

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • DNA
  • Drug Discovery
  • Genome
  • Disease
  • Antibody
  • Delivery
  • Therapeutic
  • Vaccine
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 372419

License Grant
This amendment 4 expands the field.  The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases and vaccines, and Licensee now agree to further modify the scope of the Agreement to include new patent families and expand the field to include all therapeutic applications in the Field.
License Property
The license is on a patented specific nucleotide sequence having a triplex structure, referred to as DNA flap.

Gene therapy shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein or other molecule, in order to restore the functional activity of one or more resident non-functional gene copies, or provide for the introduction and expression of novel protein(s) or molecule(s) not normally expressed in the cell type or expression of protein(s) or molecule(s) that do not exist normally in nature.  The introduced protein(s) or molecule(s) are not intended to generate a prophylactic and/or therapeutic immune response against the protein or molecule encoded by the introduced DNA sequence of interest for use in Vaccination.

Field of Use
The Field shall mean Gene therapy for the treatment and prevention of human disorders, including, without limitation, the use of chimeric antigen receptor T-cells.

Chimeric antigen receptor cells is a special receptor created in the laboratory that is designed to bind to certain proteins on cancer cells. The chimeric antigen receptor is then added to immune cells called T cells.

IPSCIO Record ID: 256218

License Grant
The Licensor of Israel grants an exclusive, worldwide royalty bearing license, with the right to grant sublicenses through multiple tiers,  under the Licensed IP Rights to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, import, export, commercialize and otherwise exploit Licensed Products for use in the Field.
License Property
The licensed patents refer to Chimeric Receptor Genes and Cells Transformed Therewith.

Eshhar patents US 5,906,936
US 7,741,465, Eshhar et al

Eshhar-NIH patent US 8,211,422, Eshhar et al

Eshhar-NIH pending application [US 13/281,560, Eshhar et al

KTE-C19 is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias.

Field of Use
The Field shall mean, collectively, all oncology applications and all other applications, as mutually agreed in writing by the parties and attached as an amendment to this Agreement.

IPSCIO Record ID: 372479

License Grant
The Parties now agree to further expand the Field to include human and non-human lentivirus.

And the grant is restated as
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is
– exclusive for Products containing or based on any lentivirus vector including human and non-human lentivirus.

In addition, Licensor grants a nonexclusive license under the Patents in the Field and in the Territory to make or to have made by a Thirty Party Good Manufacturing Practice (GMP) batches of lentiviral vectors for its/their own clinical trials on Products, provided that such Third Party makes Good Manufacturing Practice (GMP) batches of lentiviral vectors solely for the Licensee and its Affiliates and sublicensees clinical trials of Products above mentioned.

License Property
The license is on a patented specific nucleotide sequence having a triplex structure, referred to as DNA flap.

Lentivirus is a genus of retroviruses that cause chronic and deadly diseases characterized by long incubation periods, in humans and other mammalian species. The genus includes the human immunodeficiency virus, which causes AIDS.

Field of Use
The Field shall mean ex vivo Gene therapy for human disorders limited to adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD, and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), (hemophilia, lysosomal storage disorders (LSDs, including Gaucher disease, Fabry disease, Pompe disease or GAA deficiency, and mucopolysaccharidosis I, II and VI), HIV/AIDS,) leukemias, lymphomas, B-cell malignancies and solid tumors by producing chimeric antigen receptor T-cells (that target specific tumor antigens (TSA), including those TSA that are specific to B cell malignancies and solid tumors and are present only on tumor cells and not on any other cell, and/or tumor-associated antigens which are present on some tumor cells and also some normal cells, autoimmune diseases, eye diseases (including but not limited to AMD and Stargardt disease), and Parkinsons Disease); for [Parkinsons Disease,) and [eye diseases (including but not limited to AMD and Stargardt disease)).  The Field includes in vivo as well as ex vivo Gene therapy.

IPSCIO Record ID: 372469

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is
—  exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector, and;
—  non exclusive for Products containing non-human lentivirus vector.
License Property
Licensor has identified and patented a specific nucleotide sequence having a triplex structure, referred to as DNA flap, covered by patents and patent applications.

Ex vivo gene therapy shall mean that cells are extracted from a patient, corrected by placing a healthy or functional gene and transplanted back into patient.

Field of Use
Field shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy (ALO) (including but not limited to AMN, CCALD, and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to betathalassemia and sickle cell anemia), (hemophilia, lysosomal storage disorders (LSDs, including Gaucher disease, Fabry disease, Pompe disease or GAA deficiency, and mucopolysaccharidosis I, II and VI), HIV/AIDS, eye diseases (including but not limited to AMD and Stargardt disease), and Parkinsons Disease; for Parkinsons Disease and eye diseases (including but not limited to AMD and Stargardt disease)].  The Field includes in vivo as well as ex vivo gene therapy.

IPSCIO Record ID: 372471

License Grant
Licensor grants a perpetual, non-terminable, worldwide, exclusive license, with the right to sublicense, under Licensed IP to Develop and Commercialize Licensed Products in the Field.

Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.

License Property
Licensor has developed and owns or has rights to certain Patents and technology relating to developing innovative gene therapies for genetic disorders;

Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement.  Target Antigens will be limited to the oncology associated antigens designated.

T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.

Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.

The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

IPSCIO Record ID: 344487

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants to Licensee, grants the French Licensee an exclusive license for the patents to make, have made, use and sell the Licensed Products and/or implement or have implemented the Licensed Process in the Territory in the Field.

The Licensor has already granted exploitation rights under the Patents to Third Parties for the production of the enzyme I-SceI, the use of the plasmid pSCM525, and, internal research.  Consequently, the term exclusive is understood for the purposes of the present agreement as the Licensor being prohibited from exploiting or having exploited or granting a license or exploitation rights under the Patents to a Third Party in the Field, other than those already granted.

License Property
The University is the owner of patents and patent applications relating to the gene of enzyme I-SceI, the expression of the enzyme I-SceI and its use.

The patent is titled Nucleotide sequence encoding the enzyme I-SceI and the uses thereof.

Field of Use
The Field is understood as any application of the Licensed Products and Licensed Process, in particular with to homologous recombination, excluding the applications for which rights have already been granted.  Homologous recombination is a type of genetic recombination in which genetic information is exchanged between two similar or identical molecules of double-stranded or single-stranded nucleic acids (usually DNA as in cellular organisms but may be also RNA in viruses). It is widely used by cells to accurately repair harmful breaks that occur on both strands of DNA, known as double-strand breaks (DSB).

IPSCIO Record ID: 356265

License Grant
The Parties collaborate together to research, develop and commercialize therapeutic products in the Field and Licensee will have the exclusive option to take a license to each Product Candidate, whereby Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor) license, with the right to sublicense, under Licensed IP, to Develop Elected Candidate and to Develop and Commercialize Licensed Product.
License Property
Licensor patents
US 5,464,758 – Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US 5,589,362 – Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US 5,654,168 – Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The  broad, global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The collaboration will focus on applying gene therapy technology to genetically modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

Field means the use of (i) T-Cells expressing a CAR (with or without other engineering to enhance functionality and/or safety), including virus specific genetically modified T-Cells expressing a synthetic CAR, and (ii) T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under (i) and (ii) for the treatment, modulation, palliation or prevention of cancer in humans.

IPSCIO Record ID: 362483

License Grant
Licensors, as applicable, grant to Licensee of Switzerland an exclusive, sub-licensable license, under the Licensor IP in the Territory in the Field,
–  to generate and test Chimeric Antigen Receptor T-Cell Products solely for the Development, Regulatory Approval and Commercialization of Products containing such Chimeric Antigen Receptor I-Cell Products;
–  to Develop and Commercialize Products in the Field in the Territory, provided that such Products are not Out-of-Scope Products; and
–  to Commercialize the Chimeric Antigen Receptor for Products.
License Property
Licensor has expertise in and owns or controls proprietary technology relating to genetically engineering cells to target and destroy cancer cells.

Product means any pharmaceutical product containing a Chimeric Antigen Receptor I-Cell Product developed by Licensor under a Research Program for which the JSC determines to file an IND or under a research program for which Licensee has exercised the Licensor Program Option, or, any pharmaceutical product containing a Chimeric Antigen Receptor T-Cell Product developed by or on behalf of Licensee that is a derivative of or is otherwise developed from or based upon a Chimeric Antigen Receptor T-Cell Product described above.

Allogcneic Cell Therapy means a genomically engineered patient-nonspecific T-cell expressing a Chimeric Antigen Receptor for delivery to a patient developed under the Allogeneic Cell Therapy Research Program satisfying the Allogeneic Cell Therapy Criteria.

Chimeric Antigen Receptor T-Cell Product means a T-Cell having a Chimeric Antigen Receptor, or, a T-cell under switch control having a Chimeric Antigen Receptor and any Activator Ligands or Exclusive Activator Ligands that are administered to control such T-cells irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such T-cell directed to a Target, or, an Allogeneic Cell Therapy, or, the Allogeneic Cell Therapy under switch control having a Chimeric Antigen Receptor directed to a Target and any Activator Ligands or Exclusive Activator Ligands that are administered to control such Allogeneic Cell Therapy irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such Allogeneic Cell Therapy, or, any component sold as a kit, such as a device, delivery system or therapy scheme for the above to modify such T-cell including one or more polypeptides or nucleic acids encoding a CAR.

Licensor Platform Technology means Licensors platform of research tools and technology necessary for Licensor to perform its tasks directed towards the design, identification, culturing, and/or production of genetically modified cells consistent with this Agreement, including without limitation the technology embodied in the Licensor Materials and the Licensor Patents, and specifically including without limitation the following of Licensors platform areas and capabilities
(I) UltraVcctor,
(2) LEAP,
(3) DNA and RNA MOD engineering,
(4) protein engineering,
(5) transcription control chemistry,
(6) genome engineering,
(7) cell system engineering,
(8) Endometrial Regenerative Cells,
(9) the RheoSwitchE technology and RheoSwitch Therapeutic Systems, and
(10) MD Anderson CC Technologies.

Field of Use
The Field means the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans.

IPSCIO Record ID: 280819

License Grant
For the Research the German Licensor grants a non-exclusive research license under Licensor Background Inventions and Licensors rights in Collaboration Data, Collaboration Materials and Collaboration Inventions, to perform its obligations under the Collaboration Plan.

For the Commercial License,  Licensor grants an exclusive, worldwide license to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products for use in the Field directed to such Licensee Target under Licensor Background Inventions, and under Licensors rights in all Patent Rights and Collaboration Inventions and Collaboration Material pertaining to such Licensee Target and Licensed Products, or the uses thereof in the Field.

License Property
Licensors HuCAL Technologies shall mean the HuCAL library and associated technologies.   The library data is for a Design of Human Combinatorial Antibody Library-Fab (HuCAL-Fab).
Field of Use
The field shall mean all therapeutic indications.  With this agreement, the Parties will collaborate in the discovery and development of human monoclonal antibodies against certain specified Licensee Targets,  to generate and characterize antibodies and optimize those antibodies and  use their expertise in developing antibodies in pre-clinical and clinical settings.

The two companies will collaborate on the development of human antibodies for the treatment of cancer.

IPSCIO Record ID: 128301

License Grant
For the Licensee products, Licensor grants a non-exclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensor Technology and Licensor Patents to perform research and preclinical development in the Field during the research term using Licensee research genes.

Licensor grants a non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee research genes exercisable during the research term of this Agreement.

Licensor grants an exclusive worldwide license, with the right to grant sublicenses, under Licensor Technology and Patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensors patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.

IPSCIO Record ID: 203979

License Grant
Licensor grants a nonexclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensors technology and patents to perform research and preclinical development in the field during the research term using Licensee research genes.

Licensor grants non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee identified Research Genes exercisable during the research term of this Agreement.

With respect to exclusive Licensee products directed to a Licensee research gene for which Licensee has exercised an option Licensor is obligated to grant a license.  Licensor grants to Licensee an exclusive worldwide license under Licensor technology and patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensed patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.

IPSCIO Record ID: 336357

License Grant
For the Exclusive License, the French Licensor grants an exclusive, even as to, except Licensor to the extent necessary for Licensor to perform its obligations under the Research Program, license under the Licensor Intellectual Property (excluding TAL Patent Rights), to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Licensee Licensed Products in the Field in the Territory, with the right to sublicense.

For the TAL Patent Rights, Licensor grants the right to use the TAL nucleases engineered by Licensor pursuant to this Agreement to Develop Licensee license products until the filing of an IND for each Licensee Licensed Product, in the Field.

Also, for an Exclusive License, Licensor grants an exclusive ( even as to Licensor) license under the TAL Patent Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize such Licensee Licensed Product in the Field in the Territory.

For the Right of Reference, Licensor grants a Right of Reference, to any data Controlled by Licensor that relates to the Licensed Licensor Intellectual Property, the Agreement CAR-Ts, the Licensee Licensed Products or preclinical studies with respect to the Licensee Licensed Products and that Licensee reasonably believes may be necessary or useful to the Development.

For the License to Licensor Improvements, Licensor grants a nonexclusive, worldwide, sublicensable, perpetual and irrevocable license under any Licensor Improvements that were solely or jointly invented by the employees, agents or independent contractors of Licensee to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and processes.

License Property
Licensor has developed and controls proprietary rights to certain technology relating to adoptive immunotherapy CART-cell and genome engineering technologies.

Agreement CAR-T means any CAR-T utilizing the Licensor Technology that is identified, created or developed Targeting a Licensee Target.

CAR means a chimeric antigen receptor expressed from an experimentally validated Licensor viral construct with specific molecular architecture and signaling domain sequences.

CAR-T means a population of T-cells with a unique set of experimentally validated biologic attributes expressing a CAR construct produced using Licensor Technology.

Patents include
TAL Effector-mediated DNA modification,
Modular DNA binding domains and methods of use, and
Method for treating materials with pulsed electric field, and other patents.

CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient’s own T-cells to target tumor cells).

Field of Use
The global strategic collaboration is to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.

The Field means human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes.

The Parties are collaborating to discover and research novel CAR-Ts active against certain designated targets and to provide for Licensee to further research, develop, manufacture and commercialize such CAR-Ts and products containing such CAR-Ts.

IPSCIO Record ID: 372444

License Grant
The existing agreement is for the rights to use Licensor’s antibody phage display technology.  This agreement is to extend the term  and amend other terms.

Licensee shall have rights to use and practice the Licensor Technology, and Licensor licensed Patent Rights and Know-How as follows
— For the Licensor Antibody library, Licensor grants to Licensee a world-wide, nonexclusive license, without the right to grant sublicenses, to use the Licensor Antibody Library and to practice the Licensor Patent Rights solely in connection with the use of the Licensor Antibody Library to research, develop and make Antibody Compounds and a world-wide, nonexclusive license, with the right to sublicense, to use the Antibody Compounds in order to make, have made, use, sell or import Licensed Products.

For Licensor Materials, In connection with the practice of the license rights set forth, Licensor grants to Licensee a worldwide, non-exclusive, non-transferable license, without the right to grant sublicenses, to use the Licensor Materials on its own behalf only to identify Antibody Compounds from the Licensor Antibody Library and to make quantities of Antibody Compounds that are reasonably required for research and development activities only.

For the Third Party Sublicense Rights, During the library License Term, Licensee shall have rights to use and practice the Licensor licensed Patent Rights and Know-How.

License Property
Licensor possesses intellectual property and know-how related to, among other things, the discovery of antibodies having novel binding properties using phage display.

Licensed Product means any Antibody Compound or product that incorporates an Antibody Compound, whether or not conjugated to another compound that is a Therapeutic Product or an In Vitro Diagnostic Product.

The licensed library is The phagemid-based Fab library.

Licensed materials include Expression vectors pXPlsacB and pXP2sacB for soluble Fab production in E. coli. IgG expression vectors (pBRV and pShuttle) for rapid subclomng and converting Fab fragments into human IgGl and IgG4 and munne IgG2a. (Streptavidin-binding antibody clones will be provided as a positive control.)

The patents include
— Phage display patents
— Focused libraries of genetic packages
— Novel methods of constricting libraries of human FAB antibody fragments displayed on filamentous phage
— Ligand Screening and Discovery
— Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use
— Novel Plasmid Vector with Pectate Lyase Signal Sequence

Field of Use
The field of use is Therapeutic Field of Use means shall mean human therapeutics only and not for any in vitro or in vivo diagnostics, purification or separations, research products nor for any other purposes.

IPSCIO Record ID: 344477

License Grant
Licensor hereby grants to Licensee (a) an exclusive (even as to Licensor and its Affiliates), royalty bearing, sublicenseable (but only in accordance with Agreement (Sublicenses)), license under the Licensor Patents and its interest in the Collaboration Patents and (b) a non-exclusive, royalty bearing, sublicenseable (but only in accordance with Agreement  (Sublicenses)) license under the Licensor Licensed Know-How and its interest in the Collaboration Know-How, in each case, to Exploit Licensee Product(s) in the Licensed Field in the Territory during the Term.
License Property
Licensor Patents means all Patent Rights Controlled by Licensor or its Affiliates (Sale Transactions or Licensor Acquisition) that Cover the Licensor Platform Technology, including the Patent Rights listed (Licensor IP).
U.S. patent 5,906,936 – Endowing lymphocytes with antibody specificity
U.S. patent 7,741,465 – Chimeric receptor genes and cells transformed therewith
U.S. patent 6,319,494 – Chimeric chains for receptor-associated signal transduction pathways

Licensee Product means (a) as it relates to an Licensee Target, other than an Additional Target, a CAR Product directed against such particular Licensee Target based upon or generated using the constructs or complexes for CAR Products generated in the conduct of the Preclinical Development Plan for such Licensee Target; and (b) as it relates to an Licensee Additional Target (if any), either a CAR Product or a TCR Product (but not both) directed against such Additional Target based upon or generated using the constructs or complexes for CAR Products or TCR Products. as the case may be, generated in the conduct of the Preclinical Development Plan for such Additional Target.

CAR Product means a pharmaceutical or biologic product containing an adoptive T cell expressing a CAR directed against a particular Target.

Licensee Target means a Target specified as an Licensee Target  (Target Selection) or any New Target or Additional Target selected by Licensee. For clarity, Licensee Target shall exclude any Removed Target.

Target means an antigen expressed on or in a tumor cell.

Field of Use
Field of use is for the development activities of certain cell-based therapy products. Licensed Field means any and all uses.

IPSCIO Record ID: 368653

License Grant
For the options and commercial licenses, the Licensor of Switzerland, an international community of scientists focused on cancer research, grants a Non-exclusive, worldwide license, with rights to grant sub-licenses, under Licensor Patent Rights and Know-How to research, develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products in the Field.
License Property
Licensor owns or has the rights to patents including those relating to Full length Antigens and Part Length Antigens.

Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.

Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.

Field of Use
Agreement covers potential antigens being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma.

These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.

This agreements focus is cancer immunotherapy.

IPSCIO Record ID: 369313

License Grant
Licensor, a non-profit cancer treatment and research institution, grants the exclusive right and license, with the right to sublicense, to make, have made, use, lease and sell the Licensed Products in the Territory for the Field of Use.
License Property
The Invention shall mean the inventions claimed or described in Patent Rights titled Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma associated antigen.
Field of Use
Licensee is developing the MUC-1 peptide-based vaccine BLP-25 for the potential treatment of cancer. It is in phase II trials for non-small cell lung cancer (NSCLC). The MUC-1 mucin secreted by cancer cells has been shown to decrease the activity of certain immune response cells, including killer T-cells, and can inhibit the immune T-cell response by > 70%. BLP-25 is designed to target an immune response to the MUC-1 mucin that is shown by > 90% of common solid tumors.

The Field of Use shall mean in vivo, ex vivo, or in vitro prophylactic or therapeutic uses of Licensed Product in the treatment or prevention of cancer in humans.

IPSCIO Record ID: 344529

License Grant
By the original agreement, Licensor, a not-for-profit pediatric treatment and research facility, grants an exclusive license to develop, make, have made, use, import, offer for sale, sell, and have sold the Licensed Products and Licensed Services worldwide under the Patent Rights in the Licensed Field.
License Property
The licensed property is the invention(s) titled Chimeric Receptors with 4-1BB Stimulatory Signaling Domain.

This amendment #2 adds that Licensed Products shall mean, when used in relation to A Third Party Agreement, any material, cell, composition or drug, the manufacture, use, importation, offer for sale or sale of which would infringe any Valid Claim but for the license granted under the Third Party Sublicense Agreement. For the avoidance of doubt, as of the Third Party Sublicense Agreement. effective date, the Penn Construct and any product incorporating the Penn Construct are Licensed Products, and,

Adds that Licensed Services shall mean, when used in relation to the Third Party Sublicense Agreement, any service using a Licensed Product.

Penn Construct shall mean a CART-19 that includes a 4-1BB signaling domain and a CD3~ signaling domain.  CART-19 shall mean a chimeric antigen receptor T cell directed against CD 19.

Patent Rights are amended to read Patent Rights, when used in relation to the Third Party Sublicense Agreement, shall mean the patent and patent applications listed in the Third Party Sublicense Agreement;  and specifically exclude 7,435,596 and 8,026,097.

Field of Use
The shall mean all therapeutic, diagnostic, preventative and palliative uses.

Licensee is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Chimeric antigen receptor (CAR) recognize and kill cancer cells.

IPSCIO Record ID: 110461

License Grant
The University grants to Licensee and its Affiliates the exclusive license in the Territory with the right to grant sublicenses to others, under the Patent Rights, to make, have made, use, sell, import and offer for sale Products and to practice Processes.

Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor.

License Property
The licensed patent applications relate to a Modified Heat Shock Protein-Antigenic Peptide Complex.
Field of Use
The licensed patent is in the area of the use of heat shock proteins for the development of therapeutic and prophylactic vaccines for cancer and infectious diseases (the 'Field').

IPSCIO Record ID: 299303

License Grant
Licensor shall grant to Irish Licensee and any Licensee Development Partner of whom Licensee provides written notice to Licensor an exclusive, worldwide, royalty-bearing license and right under the Licensor Patent Rights and/or any other patents, patent applications or intellectual property owned or licensed by Licensor (with the right to license or sublicense), which claim or cover a given Licensee Development Product or its manufacture or use to make, have made, use, sell, offer to sell, import, export, develop, commercialize and manufacture such Licensee Development Product. During the pendency of each Licensee Project and for a period of eighteen months (18) thereafter, Licensor covenants that it will not conduct any activities on its own behalf or on behalf of a Third Party which relates to or encompasses the Licensee Target that is the subject of such Licensee Project.
License Property
Antibody Evolution means the alteration of the nucleic acids encoding an Immunoglobulin by saturation mutagenesis as described in the Licensor Patent Rights, by means other than Antibody Phage Display.

Licensor Patent Rights means the inventions patentable under applicable patent law that are claimed in the patent applications and patents listed (a) hereto and all divisions, continuations, continuations-in-part, applications claiming priority thereto, and substitutions thereof; all foreign patent applications corresponding to the preceding applications; all U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues and re-examinations; and any patents or patent applications, whether now existing or obtained in the future, owned or controlled by Licensor containing a claim that is dominating over the foregoing patent rights (i.e., is necessarily infringed by the practicing of a claim in one of the foregoing applications); and any patents or patent applications covered by any Licensor Third Party Licenses, a list of which is set forth.
6,171,820 – Saturation mutagenesis in directed evolution
6,479,258 – Non-stochastic generation of genetic vaccines

Licensor Evolution Technologies means the inventions patentable under applicable patent law that are claimed in the Licensor Patent Rights which both (a) are owned or controlled by Licensor and (b) either (i) comprise evolution of a gene and/or gene pathway by changing more than 50% of the codons and/or amino acids of such gene and/or genepathway to more than 50% of every other possible codon and/or amino acid or such gene and/or gene pathway, or (ii) comprise evolution of a gene and/or gene pathway by creating and screening a non-stochastically produced library of molecules by combining tragments of a plurality of genes chosen by design to reassemble compleete genes and/or gene pathways according to the patentable methods embodied by inventions described in the Licensor Patent Rights.

Licensed Immunoglobulin means (a) with respect to the licenses and rights granted, any Immunoglobulin discovered, isolated or characterized by Licensor through the use of Antibody Evolution, and (b) with respect to the licenses granted, Licensed Immunoglobulin includes any Immunoglobulin discovered using Antibody Evaluation but outside the Manufacturing Field, and for purposes of this agreement hereof, Licensed Immunoglobulin includes any Immunoglobulin within the Manufacturing Field.

Licensed Immunoglobulin Information means any data, know-how or other information relating, concerning or pertaining to a Licensed Immunoglobulin, including without limitation data, know-how or other information characterizing or constituting such Licensed Immunoglobulins polynucleotide or amino acid sequence, purported function or utility, antigen binding affinity, or physical or biochemical property.

Immunoglobulin means any molecule, including without limitation, full immunoglobulin molecules (e.g., IgG, IgM, IgE, IgA and IgD molecules) and ScFv, Fv and Fab molecules, that has an amino acid sequence by virtue of which it specifically interacts with an antigen and wherein that amino acid sequence consists essentially of a functionally operating region of an antibody variable region including without limitation any naturally occurring or recombinant form of such a molecule.

Licensee Patent Rights means the inventions patentable under applicable patent law that are claimed in the patent applications and patents listed hereto and all divisions, continuations, continuations-in-part, applications claiming priority thereto, and substitutions thereof; all foreign patent applications corresponding to the preceding applications; all U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues and re-examinations; and any patents or patent applications, whether now existing or obtained in the future, owned or controlled by Licensee containing a claim that is dominating over the foregoing patent rights (i.e., is necessarily infringed by the practicing of a claim in one of the foregoing applications).
5,595,898 – Modular assembly of antibody genes, antibodies prepared thereby and use
6,204,023 – Modular assembly of antibody genes, antibodies prepared thereby and use

Licensee Technology Platform means all know-how, trade secrets, inventions, data, processes, procedures, devices, methods, formulas, media and all cell lines, reagents, protocols and other information, whether or not patentable, that either (a) constitute or relate to any biological target, antigen, receptor, cell, expression vector, disease, condition, nucleic acid, protein (including, without limitation, an Immunoglobulin) or protein-conjugate which is the subject of or arises out of any Licensee Project or (b) relate to the discovery, optimization, expression or manufacture of Immunoglobulins, in each case which are owned by or licensed to Licensee as of the Effective Date and are disclosed to Licensor or used by Licensor or Licensee in connection with a Licensee Project. For the avoidance of doubt, the term 'Licensee Platform Technology' shall include any prokaryotic expression technology and methods and/or antibody phage display technology and methods.

Licensor Collaborator means any person or entity on whose behalf Licensor engages in Antibody Evolution and/or a person or entity who is the intended recipient of Licensed Immunoglobulins or Licensed Immunoglobulin Information transferred from Licensor.

Licensee Development Product means any composition of matter or article of manufacture consisting essentially of an Immunoglobulin or protein discovered or optimized by Licensor for Licensee pursuant to a Licensor Action Plan and where such Immunoglobulin or protein was discovered or optimized using techniques, methods or materials covered by one or more Valid Claims of any patent or patent application controlled by Licensor, including the Licensor Patent Rights.

Field of Use
The collaborative agreement is to develop optimized therapeutic antibodies.

Licensor Field means (a) Research and Development and (b) the diagnosis, treatment, prevention or prophylaxis of any human or animal condition or disease. The Licensor Field shall not include any Non-Approved Uses.

Manufacturing Field means the production in prokaryotes of an Immunoglobulin for the treatment, diagnosis or prophylaxis of a human or animal disease or condition in quantities which exceed Research Quantities, and shall include commercial, industrial or clinical scale production.

IPSCIO Record ID: 369311

License Grant
Licensor of the Netherlands grants to Licensee of Germany a license under the Licensor Technology  to use, import, develop, market and sell and have used, imported, developed, marketed and sold product in the Field in the NA Territory and the ROW Territory.

This agreement includes a non-exclusive grant back to Licensor by Licensee.

License Property
Licensor has technology related to, inter alia, the development of BLP25.

The Product means BLP25.

BLP25 means Licensors immunotherapeutic vaccine composed of a 25-amino acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant Lipid A and is encapsulated in a liposomal delivery system, together with any improvements thereto, such as liposomal IL-2 in a kit, synthetic Lipid A, or new delivery formats such as unit dose liquid formulations and unit dose syringes.

MUC1 means cancer associated mucin-1.

L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. It is designed to induce an immune response to both the synthetic antigen and the natural corresponding antigen as expressed on the cancer.

Field of Use
BLP25 Liposome Vaccine (L-BLP25) is currently in development for the treatment of non-small cell lung cancer (NSCLC).  Licensee will take over administrative and financial responsibility for the development and commercialization of L-BLP25, including the planned phase 3 trial in NSCLC

The field shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.